Impact of Vasopressin on Kidney and Heart Function in Septic Shock
Effect of Vasopressin on Kidney and Cardiac Function in Previously Hypertensive Patients With Septic Shock: A Randomized Clinical Trial
NA · Pontificia Universidad Catolica de Chile · NCT06125184
This study is testing whether vasopressin can help improve kidney and heart function in patients with septic shock who have high blood pressure and aren't responding to regular treatments.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pontificia Universidad Catolica de Chile (other) |
| Locations | 1 site (Santiago, Metropolitana) |
| Trial ID | NCT06125184 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of vasopressin on kidney and cardiac function in patients experiencing septic shock, a critical condition often leading to organ failure. It focuses on patients with a history of chronic hypertension who are unresponsive to fluid resuscitation and require norepinephrine to maintain blood pressure. The intervention involves a vasopressor test to assess improvements in organ function and hemodynamics. The study aims to optimize treatment strategies for septic shock and reduce the incidence of acute kidney injury.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with septic shock who have a history of chronic hypertension and are mechanically ventilated.
Not a fit: Patients under 18 years old, those with severe heart disease, or those who have been diagnosed with septic shock for more than 24 hours may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney and heart function in patients with septic shock, potentially reducing mortality and the need for renal replacement therapy.
How similar studies have performed: Previous studies have shown that optimizing mean arterial pressure can improve renal function in septic shock patients, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Septic shock diagnosed at ICU admission according to the Sepsis-3 * Mechanical ventilation in place * Past medical history of chronic hypertension * Fluid unresponsive status * Stable norepinephrine dose ≥ 0.1 mcg/kg/min * Persistent tissular hypoperfusion after initial resuscitation Exclusion Criteria: * Age \< 18 years * \> 24 h since septic shock diagnosis * Moderate or severe mitral/aortic disease * Anticipated surgery during the study period * Abdominal hypertension grade III * Pregnancy * Do-not-resuscitate status
Where this trial is running
Santiago, Metropolitana
- Hospital Clínico Pontificia Universidad Católica de Chile — Santiago, Metropolitana, Chile (RECRUITING)
Study contacts
- Principal investigator: Emilio Daniel Valenzuela Espinoza, MD — Pontificia Universidad Catolica de Chile
- Study coordinator: Emilio Daniel Valenzuela Espinoza, MD
- Email: ed.valenzuela.e@gmail.com
- Phone: 56965329099
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Injury, Acute, Cardiac Function Failed